# Egalet Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/egalet

- Industry: Pharmaceuticals
- Headquarters: Wayne, US
- Website: www.egalet.com
- Total disclosed funding: $44M
- Latest round: Series C (Sep 12, 2013)
- Investors on record: 10

## About

Egalet Corporation is a pharmaceutical company dedicated to developing innovative solutions for pain management, focusing on minimizing misuse risks while delivering effective treatment options.Egalet Corporation specializes in creating pharmaceutical products aimed at pain management. Founded in 1995 in Wayne, US, the company has undergone several strategic adjustments to enhance its offerings. Notably, on February 7, 2014, Egalet launched an IPO, raising USD 50.4 mn from the public market. The company has completed a total of 7 deals, with its most recent funding coming through a VENTURE DEBT round amounting to USD 40.00 mn.Egalet Corporation specializes in the development and commercialization of innovative pharmaceutical products, particularly in pain management. The company’s core offerings are designed to provide solutions for patients requiring effective pain relief while minimizing the risks of misuse and abuse. Their flagship product, a unique formulation of an opioid analgesic, is engineered to deter tampering and misuse, addressing critical concerns in pain management. Egalet's products are primarily targeted toward healthcare providers, including pain specialists and general practitioners, as well as patients with chronic pain conditions. The company operates within multiple geographical markets, focusing on the United States and select international regions, ensuring their products meet the diverse needs of patients globally.Egalet Corporation generates revenue through direct sales of its pharmaceutical products to healthcare providers and distributors. For the year 2019, the company recorded a revenue of USD 79.53 mn, with an EBITDA of USD -22.06 mn. The company’s transaction structure typically involves B2B sales where products are sold through wholesale distributors, pharmacies, and directly to healthcare institutions. Revenue is derived from prescription sales of its proprietary formulations, with terms negotiated in accordance with market conditions and the specific needs of its clients. Pricing plans are established based on the value proposition of their products, considering factors such as efficacy and safety profiles, particularly for their trademarked formulations. The structured approach to transactions helps ensure steady revenue streams while emphasizing product integrity and patient safety.Egalet Corporation is strategically poised for future growth, focusing on the development of new pharmaceutical products aimed at expanding its pain management portfolio. The recent funding of USD 40.00 mn from the VENTURE DEBT round will support these initiatives. The company is also looking to expand its geographical footprint into additional international markets several years ahead, enhancing its existing distribution channels. The funding from the IPO launched in February 2014 will be critical in supporting these upcoming launches and market expansions.

## Funding rounds

- Series C, Sep 12, 2013, $10M — Index Ventures
- Series B, May 7, 2012, $14M — Atlas Venture, Index Ventures, Heartcore Capital, Omega Funds, Enso Ventures
- Series B, Apr 2, 2007, $19M — Atlas Venture, Index Ventures, Bio Fund Management, DKA Capital, Danske Bank, Vaekstfonden, QueQuoin Holdings Ltd.

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series B
- Index Ventures (https://capitalatlas.ai/funds/index-ventures) — Series B, Series C
- Bio Fund Management (https://capitalatlas.ai/funds/bio-fund-management) — Series B
- DKA Capital (https://capitalatlas.ai/funds/dka-capital) — Series B
- Danske Bank — Series B
- Vaekstfonden (https://capitalatlas.ai/funds/vaekstfonden) — Series B
- QueQuoin Holdings Ltd. — Series B
- Heartcore Capital (https://capitalatlas.ai/funds/heartcore-capital) — Series B
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series B
- Enso Ventures (https://capitalatlas.ai/funds/enso-ventures) — Series B